Recombinant human IgA-J chain dimer

US6673342B1 · kind B1 · utility

Assignees

• Bond of Regents, The University of Texas System · US
• The United States of America, as represented by the Department of Health and Human Services · US

Inventors

• J. Donald Capra · Dallas, US
• Jonathan Mark Hexham · Dallas, US
• Leon N. Carayannopoulos · Chesterfield, US
• Edward E. Max · Bethesda, US

Key dates

• Filing date: May 16, 2000
• Grant date: Jan 6, 2004
• Expiry date: May 16, 2020

Classification

• Technology area (CPC Y): Emerging Cross-Sectional Technologies
• CPC primary: Y02A50/30
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Disclosed are compositions and methods of use that comprise engineered IgA antibodies that, when administered to a host are secreted across the epithelium into the mucosal barriers of the body providing external passive immunotherapy against agents such as viral, bacterial and eukaryotic pathogens. Also disclosed are mini antibodies comprising the minimal transcytosis domains.